STERLING WINSTROL (STANOZOLOL) NDA WITHDRAWAL PROCESS BEGINNING, FDA announced in an April 23 Federal Register notice. In the notice the agency offered an opportunity for a hearing on the anabolic steroid's two labeled indications, adjunctive treatment of "senile and postmenopausal osteoporosis" and use in raising hemoglobin levels in aplastic anemia patients. The document also revoked the "temporary exemption" that has permitted the drug to remain marketed beyond the initial time limits set for the DESI review. FDA explained that it agreed with the conclusions of its Endocrinologic & Metabolic Drugs Advisory Cmte., which last year declined to recommend approval for either indication ("The Pink Sheet" Sept. 26, T&G-1 and May 23, T&G-2). In January of this year, the cmte. reviewed the drug for use in vascular disorders associated with reduced fibrinolysis and concluded that, while Winstrol favorably influenced biochemical parameters, additional data is needed to establish clinical effectiveness ("The Pink Sheet" Jan. 30, p. 13). Regarding the osteoporosis indication, FDA asserted that the one clinical study, the Chestnut study, submitted by the firm cannot by itself support the claim. FDA pointed out that Sterling does have a second clinical trial underway in the U.K., but that the trial "is not expected to be completed for several years." In the Chestnut study, "although a statistically significant difference between Winstrol and control groups was obtained for total body calcium in the analysis presented by Sterling, this finding is sensitive to the handling of data on patients withdrawn from the study and the method of analysis used," FDA explained. The agency said when dropouts are included in the analysis, the results lose their statistical significance. Further, FDA expressed concern about hepatotoxicity and effects on the cardiovascular system, especially in view of the large patient population. Requests for hearing are due by May 23.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.
